• OCT 26 2017

    ONC201 Biomarkers and Pharmacology at ENA Conference October 27-29th in Philadelphia

    Three abstracts involving Oncoceutics’ lead clinical compound, ONC201, will be presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia on October 28th and 29th, 2017. ONC201 is the first Dopamine Receptor 2 (DRD2) antagonist for clinic oncology and the first imipridone to enter the clinic, with 8 active clinical trials

    • SEP 25 2017

    Oncoceutics to Present Imipridone Class at Discovery On Target Conference

    At the upcoming Cambridge Healthtech Institute’s 12th Annual GPCR-Based Drug Discovery conference, September 26th and 27th in Boston, Oncoceutics will be presenting data on the company’s lead imipridone ONC201, and other members of the imipridone class. On September 26th at 11:55am, Dr. Varun Prabhu will present “Imipridones: A New Class of Anti-Cancer Small Molecules that Selectively Engage GPCRs.”